Conclusions
Collectively, surgery may benefit patients with resectable PSC, early detection and diagnosis are still the best way to obtain the chance of radical surgery. While chemo-, antiangiogenetic- and immunochemical- therapy may be useful in controlling the progression of advanced PSC, relieving symptoms, and extending survival. However, surgical resection after chemo-, antiangiogenetic- and/or immunochemical- therapy must be carefully considered in light of the patient’s unique situation. surgical resection after adjuvant therapy must be carefully considered in light of the patient’s unique situation. In particular, accurate tumor cell genetic testing or molecular pathological diagnosis plays a key role in the individualized treatment of PSC, which could benefit patients with advanced PSC.